Skip to main content
. 2019 Nov 10;9(1):290–301. doi: 10.1002/cam4.2655

Figure 3.

Figure 3

Efficacy of CK20/CD45/CD11b for discriminating cancer cells from healthy urothelial cells and WBCs captured by NS. CK20 was used as the main marker to detect urothelial cancer cells. CD45 and CD11b were used to mark WBCs and myeloid derivatives, respectively. (A) Graph showing the comparison of CK20 and EpCAM. The immunofluorescence tests were conducted on cell lines (T24, 5637, SV‐HUC‐1) and WBCs. Each cell line was divided into two parts, one part was for CK20 experiment and the other was for EpCAM experiment. CD45 and CD11b were tested in both CK20 experiment and EpCAM experiment. CK20 showed good discriminatory ability. T24 and 5637 cells were CK20+CD45−CD11b−, SV‐HUC‐1 cells were CK20−CD45−CD11b− and WBCs were CK20−CD45+CD11b+. The combination of CK20, CD45, and CD11b demonstrated excellent ability to identify urothelial cancer cells. (B) Graph showing CK20/CD45/CD11b staining of UTCs and WBCs in urine sample isolated on NS. In the preliminary study, we validated the efficacy of CK20/CD45/CD11b marker combination in a large number of urine samples from bladder cancer patients. Here we show a representative example of such experiments, suggesting good ability of UTC assay in detecting UTCs in urine. UTC = urinary tumor cell